Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxybutynin and the overactive bladder.

K E Andersson1, C R Chapple

  • 1Department of Clinical Pharmacology, Lund University Hospital, Sweden. Karl-Erik.Andersson@klinfarm.lu.se

World Journal of Urology
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complications of Synthetic Midurethral Slings: Is There a Relevant Discrepancy Between Observational Data and Clinical Trials?

European urology focus·2023
Same author

Editorial Comment.

The Journal of urology·2021
Same author

Functional and radioligand binding characterization of the α1L-adrenoceptor subtype of the human vas deferens.

Autonomic & autacoid pharmacology·2015
Same author

The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2015
Same author

Tissue engineered buccal mucosa for urethroplasty: progress and future directions.

Advanced drug delivery reviews·2014
Same author

Contemporary issues with pharmacotherapy for lower urinary tract symptoms.

International journal of clinical practice·2014
Same journal

Safety and efficacy of different surgical approaches in single-port robot-assisted radical prostatectomy based on propensity score matching analysis.

World journal of urology·2026
Same journal

Intrarenal pressure and clinical outcomes during suction-assisted versus conventional percutaneous nephrolithotomy: a systematic review and meta-analysis.

World journal of urology·2026
Same journal

AI-driven model for early failure prediction after HIFU integrating immediate post-ablation ultrasound and clinical data.

World journal of urology·2026
Same journal

Comment on "Nurse-led postoperative telemonitoring program following outpatient urethroplasty: a pilot study".

World journal of urology·2026
Same journal

What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.

World journal of urology·2026
Same journal

Modified HoLEP technique: does it preserve ejaculation?

World journal of urology·2026
See all related articles

Oxybutynin effectively treats overactive bladder (OAB) through its antimuscarinic action, primarily via its active metabolite. While generally effective, antimuscarinic side effects can limit its use in some patients.

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Oxybutynin is a tertiary amine extensively metabolized via first-pass effect.
  • Its active metabolite, N-desethyl oxybutynin, largely mediates the effects of oral oxybutynin.
  • Oxybutynin possesses antimuscarinic, direct muscle relaxant, and local anesthetic properties.

Purpose of the Study:

  • To review the efficacy and side effect profile of oxybutynin in treating overactive bladder (OAB).
  • To highlight oxybutynin's role as a first-line treatment for detrusor overactivity.

Main Methods:

  • Review of existing studies on oral and intravesical oxybutynin for OAB.
  • Analysis of oxybutynin's pharmacological actions, including its antimuscarinic effects.
  • Consideration of adverse effects and the introduction of a controlled-release formulation.

Related Experiment Videos

Main Results:

  • Oral oxybutynin demonstrates efficacy in controlling OAB, largely due to its antimuscarinic action.
  • Intravesical administration can increase bladder capacity and improve symptoms in various OAB types.
  • Antimuscarinic side effects occur frequently, leading to discontinuation in up to 25% of patients.

Conclusions:

  • Oxybutynin is a well-established and effective treatment for detrusor overactivity.
  • It is considered a drug of first choice for patients with this condition.
  • A controlled-release formulation may mitigate some adverse effects, improving patient adherence.